Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Study of Therapeutic Effect of Different Concentrations of Imatinib on Balb/C Model of Cutaneous Leishmaniasis Publisher



Moslehi M1 ; Namdar F2 ; Esmaeilifallah M2 ; Iraji F3 ; Vakili B2 ; Sokhanvari F1 ; Hosseini SM4 ; Khamesipour F5, 6 ; Sebghatollahi Z2 ; Hejazi SH1, 2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Department of Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Department of Dermatology, Isfahan University of Medical Sciences, Isfahan, Iran
  4. 4. Department of Biostatistics & Epidemiology, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran
  5. 5. Sabzevar University of Medical Sciences, Sabzevar, Iran
  6. 6. Shahid Beheshti University of Medical Sciences, Tehran, Iran

Source: AIMS Microbiology Published:2020


Abstract

Leishmaniasis, as a tropical and subtropical disease, is endemic in more than 90 countries around the world. Today, cutaneous leishmaniasis (CL) that affects more than 1.5 million people per year lacks a definitive treatment approach. Imatinib is an anticancer drug that inhibits the abnormal function of Bcr-Abl due to its tyrosine kinase inhibitor, and that was the reason why the drug was tested for CL treatment because protein kinases are essential enzymes in the Leishmania genus. In this study, the L. major CL model of Balb/c mice was produced by injection of the cultured metacyclic form of parasite at the base of the tail. The possible recovery of CL ulcers and determination of the optimum dose of imatinib against Leishmania amastigotes were evaluated. A significant decrease was observed in mice treated with amphotericin B (positive control group) as well as imatinib 50 mg/kg compared to the unreceived drug, negative control group (P<0.05). This study could be promising in gaining insight into the potential of imatinib as an effective treatment approach against CL. © 2020 the Author(s), licensee AIMS Press.
Related Docs
View other Related Docs
1. Evaluation of Different Concentrations of Imatinib on the Viability of Leishmania Major: An in Vitro Study, Advanced Biomedical Research (2019)
2. Recombinant C-Reactive Protein: A Potential Candidate for the Treatment of Cutaneous Leishmaniasis of Balb/C Mice Caused by Leishmania Major, Acta Parasitologica (2021)
3. Anti-Leishmania Activity of Osthole, Pharmacognosy Research (2016)
4. The Effects of Prednisolone and Mometasone on Wound Healing Caused by Leishmania Major in Balb/C Mice, Journal of Isfahan Medical School (2020)
5. Evaluation of the Antileishmanial Effect of Polyclonal Antibodies and Cationic Antimicrobial Peptides, Pathogens and Global Health (2023)
6. Investigating in Vitro Anti-Leishmanial Effects of Silibinin and Silymarin on Leishmania Major, Annals of parasitology (2018)
7. A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Itraconazole in the Treatment of Cutaneous Leishmaniasis, Journal of the European Academy of Dermatology and Venereology (2005)
8. Effect of Leishmania Gerbilli Injection on Mice Immunization Against Cutaneous Leishmaniasis (Cl) Caused by Leishmania Major, Pakistan Journal of Biological Sciences (2007)
Experts (# of related papers)
View all Related Experts
Seyed Hossein Hejazi (62)
Sedighe Saberi (15)
Other Related Docs
9. Anti-Leishmaniasis Effect of Staphylococcus Aureus Protein a on the Size of the Lesion and Parasitic Load, Advanced Biomedical Research (2023)
10. Therapeutic Effect of Topical Tamoxifen in Murine Cutaneous Leishmaniasis Caused by Leishmania Major, Antimicrobial Agents and Chemotherapy (2024)
11. Efficacy of Adjunctive Topical Liposomal Clarithromycin on Systemic Glucantime in Old World Cutaneous Leishmaniasis: A Pilot Clinical Study, Frontiers in Pharmacology (2023)
12. Review of the Prevalence and Causes of Antimony Compounds Resistance in Different Societies: Review Article, Tehran University Medical Journal (2017)
13. The Role of Liposomal Cpg Odn on the Course of L. Major Infection in Balb/C Mice, Iranian Journal of Parasitology (2010)
14. Immunization Against Leishmania Major Using Uv-Irradiated Promastigote in Experimental Model Balb/C Mice, Biochemical and Cellular Archives (2017)
15. Treatment Role of Terpenoid Fraction of Perovskia Abrotanoides Kar. on Zoonotic Cutaneous Leishmaniasis in Animal Model, Traditional and Integrative Medicine (2022)
16. Treatment of Recurrent Cutaneous Leishmaniasis, International Journal of Dermatology (1995)
17. Comparison of Three Different Therapies for Cutaneous Leishmaniasis and Identification of the Etiologic Isolates in Isfahan, Iran, Archives of Iranian Medicine (2020)
18. Development of Liposomes Loaded With Anti-Leishmanial Drugs for the Treatment of Cutaneous Leishmaniasis, Journal of Liposome Research (2013)
19. Antimonial Treatment Failure Rate in Patients With Cutaneous Leishmaniasis, Tehran University Medical Journal (2018)
20. Efficacy of Paromomycin Ointment in the Treatment of Cutaneous Leishmaniasis: Results of a Double-Blind, Randomized Trial in Isfahan, Iran, Annals of Tropical Medicine and Parasitology (2005)
21. Effect of Combination Therapy With Systemic Glucantime and Pentoxifylline in the Treatment of Cutaneous Leishmaniasis, International Journal of Dermatology (2006)
22. Butanol Fraction of Kelussia Odoratissima Mozaff Inhibits the Growth of Leishmania Major Promastigote and Amastigote, World's Veterinary Journal (2020)
23. In Vitro Antileishmanial Activity of Falcaria Vulgaris Fractions on Leishmania Major, Jundishapur Journal of Natural Pharmaceutical Products (2017)
24. Immune Response Measured in Human Volunteers Vaccinated With Autoclaved Leishmania Major Vaccine Mixed With Low Dose of Bcg, Clinical and Experimental Immunology (2003)
25. Treatment of Cutaneous Leishmaniasis With Ketoconazole Cream, Journal of Dermatological Treatment (2003)
26. Isolation of Bacteria Causing Secondary Bacterial Infection in the Lesions of Cutaneous Leishmaniasis, Indian Journal of Dermatology (2008)
27. In Vitro Study of the Leishmanicidal Activity of Perovskia Abrotanoides Terpenoid-Rich Fractions Against Leishmania Major (Mrho/Ir/75/Er), Advanced Biomedical Research (2023)
28. The Study of the Inhibitory Effects of Aqueous and Ethanolic Extracts of Ziziphora Tenuior L. on the Proliferation of Leishmania Major Amastigotes, Iranian Journal of Dermatology (2018)
29. A Randomised, Double-Blind, Controlled Trial of a Killed L. Major Vaccine Plus Bcg Against Zoonotic Cutaneous Leishmaniasis in Iran, Vaccine (1999)
30. Topical Effectiveness of Different Concentrations of Nanosilver Solution on Leishmania Major Lesions in Balb/C Mice, Journal of Vector Borne Diseases (2012)
31. Identification of Leishmania Species and Treatment Courses in Patients With Leishmaniasis in Isfahan, Iran, Journal of Isfahan Medical School (2012)
32. Treatment of Acute Cutaneous Leishmaniasis With Intralesional Injection of Meglumine Antimoniate: Comparison of Conventional Technique With Mesotherapy Gun, International Journal of Dermatology (2010)
33. Comparison of Protein Profile of Killed and Autoclaved Leishmania Major Using Polyacrylamide Gel Electrophoresis, Journal of Isfahan Medical School (2013)
34. Evaluation of the 11-Year Trend of Cutaneous Leishmaniasis in Six Main Foci of the Disease in Isfahan Province During the Years 2008 to 2018, Journal of Isfahan Medical School (2022)
35. Detection of Leishmania Parasites From Cutaneous Leishmaniasis Patients With Negative Direct Microscopy Using Nnn and Pcr-Rflp, Journal of Isfahan Medical School (2012)
36. Efficacy of Integrated Pest Management in Controlling and Preventing Zoonotic Cutaneous Leishmaniasis in Isfahan Province, Iran, Journal of Isfahan Medical School (2012)
37. Effects of S-Allyl-Cysteine on Survival, Apoptosis, and Proliferation of Leishmania Major in Vitro, Journal of Isfahan Medical School (2013)
38. In Vitro Anti-Leishmanial Activity of Satureja Hortensis and Artemisia Dracunculus Extracts on Leishmania Major Promastigotes, Journal of Parasitic Diseases (2016)
39. Cutaneous Necrosis After the Injection of Sodium Stibogluconate for the Treatment of Cutaneous Leishmaniasis: A Rare Case Report, Journal of Isfahan Medical School (2019)
40. Treatment of Cutaneous Leishmaniasis: Cassia Fistula Fruit Gel-Intralesional Glucantime Vs. Placebo Gel- Intralesional Glucantime Combination, Tehran University Medical Journal (2010)
41. Serum Monocyte Chemotactic Protein-1 and Nitric Oxide in Cutaneous Leishmaniasis Patients Before and After Treatment With Glucantime, Journal of Isfahan Medical School (2012)
42. Epidemiological Aspects of Cutaneous Leishmaniasis in Iran, Archives of Clinical Infectious Diseases (2015)
43. Comparison of Intralesionally Injected Zinc Sulfate With Meglumine Antimoniate in the Treatment of Acute Cutaneous Leishmaniasis, Dermatology (2004)
44. Combinatorial Delivery of Antigen and Tlr Agonists Via Plga Nanoparticles Modulates Leishmania Major-Infected-Macrophages Activation, Biomedicine and Pharmacotherapy (2021)
45. Anti-Leishmanial Effects of Resveratrol and Resveratrol Nanoemulsion on Leishmania Major, BMC Microbiology (2022)
46. Nramp1 Gene Polymorphisms and Cutaneous Leishmaniasis: An Evaluation on Host Susceptibility and Treatment Outcome, Journal of Vector Borne Diseases (2016)
47. Comparative Molecular Epidemiology of Leishmania Major and Leishmania Tropica by Pcr-Rflp Technique in Hyper Endemic Cities of Isfahan and Bam, Iran, Case Reports and Clinical Practice Review (2010)
48. Bacterial Superinfection in Zoonotic Cutaneous Leishmaniasis, Medical Science Monitor (2012)
49. The Characterization and Antileishmanial Evaluation on Leishmania Major With Chitosan/Zno Bio-Nanocomposite As Drug Delivery Systems, Nanomedicine Research Journal (2022)
50. Electrocardiographic Changes in Patients With Cutaneous Leishmaniasis Treated With Systemic Glucantime, Annals of the Academy of Medicine Singapore (2008)